MindWalk (NASDAQ:HYFT – Get Free Report) and Ginkgo Bioworks (NYSE:DNA – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.
Earnings & Valuation
This table compares MindWalk and Ginkgo Bioworks”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MindWalk | $11.24 million | 5.94 | -$10.11 million | ($0.26) | -5.50 |
| Ginkgo Bioworks | $170.15 million | 4.50 | -$312.76 million | ($5.01) | -2.27 |
Institutional and Insider Ownership
6.7% of MindWalk shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 6.8% of MindWalk shares are held by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings and price targets for MindWalk and Ginkgo Bioworks, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MindWalk | 1 | 1 | 2 | 1 | 2.60 |
| Ginkgo Bioworks | 2 | 2 | 0 | 0 | 1.50 |
MindWalk currently has a consensus target price of $5.00, suggesting a potential upside of 249.65%. Ginkgo Bioworks has a consensus target price of $6.33, suggesting a potential downside of 44.32%. Given MindWalk’s stronger consensus rating and higher probable upside, analysts clearly believe MindWalk is more favorable than Ginkgo Bioworks.
Profitability
This table compares MindWalk and Ginkgo Bioworks’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MindWalk | -105.11% | -133.26% | -77.78% |
| Ginkgo Bioworks | -259.96% | -60.27% | -26.88% |
Volatility and Risk
MindWalk has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500.
Summary
MindWalk beats Ginkgo Bioworks on 8 of the 15 factors compared between the two stocks.
About MindWalk
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for MindWalk Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MindWalk and related companies with MarketBeat.com's FREE daily email newsletter.
